Abstract | G protein-coupled receptors (GPCRs) are the most intensively studied drug targets, mostly due to their substantial involvement in human pathophysiology and their pharmacological tractability. Here, we report an up-to-date analysis of all GPCR drugs and agents in clinical trials, which reveals current trends across molecule types, drug targets and therapeutic indications, including showing that 475 drugs (~34% of all drugs approved by the US Food and Drug Administration (FDA)) act at 108 unique GPCRs. Approximately 321 agents are currently in clinical trials, of which ~20% target 66 potentially novel GPCR targets without an approved drug, and the number of biological drugs, allosteric modulators and biased agonists has increased. The major disease indications for GPCR modulators show a shift towards diabetes, obesity and Alzheimer disease, although several central nervous system disorders are also highly represented. The 224 (56%) non-olfactory GPCRs that have not yet been explored in clinical trials have broad untapped therapeutic potential, particularly in genetic and immune system disorders. Finally, we provide an interactive online resource to analyse and infer trends in GPCR drug discovery. NATURE REVIEWS | DRUG DISCOVERY VOLUME 16 | DECEMBER 2017 | 829 ANALYSIS © 2 0 1 7 M a c m i l l a n P u b l i s h e r s L i m i t e d , p a r t o f S p r i n g e r N a t u r e . A l l r i g h t s r e s e r v e d .
. GPCRs form the largest human membrane protein family, with ~800 members overall (of which ~400 are olfactory receptors that are not included in this analysis). The GPCR superfamily has been sub-divided into classes 3 based on evolutionary homology and receptor families 4 with common physiological ligands, which are strikingly diverse: spanning ions, small molecular signalling molecules, lipids, peptides and proteins 5 . New avenues for GPCR drug discovery have emerged owing to recent advances in receptor pharmacology, breakthroughs in structural biology and innovations in biotechnology. Modulation of GPCRs via allosteric sites, which are distinct from binding sites for endogenous ligands, can alter the structure, dynamics and function of the receptor to achieve a potential therapeutic advantage, such as increased spatial and temporal selectivity 6 . Furthermore, our knowledge of receptor activation has increased with the concept of biased agonism 7, 8 -preferentially activating the desired intracellular signalling pathway while minimizing undesired side effects due to the activation of other pathways. So far, drugs targeting GPCRs have generally been developed without the help of high-resolution structural information, but the crystal structures of 44 unique receptors and 205 ligandreceptor complexes now provide a plethora of templates for structure-based drug discovery and design. Of the non-olfactory GPCRs, 130 (33%) are peptide or protein receptors that are potential targets for biological drugs, and many more receptors have become accessible through advances in techniques that exploit natural protein-protein interactions or that help develop specific antibodies and derivatives. This has led to new opportunities for both novel and established GPCR targets.
Recent reviews on GPCRs have described drug target families [9] [10] [11] , disease indications [12] [13] [14] , novel tools 15, 16 or drug discovery mechanisms [17] [18] [19] [20] . Here, we report an analysis of all GPCR drugs and agents in clinical trials, which reveals the current trends across all molecule types, drug targets and therapeutic indications. General drug discovery trends, such as biologics, allosteric modulators, repurposing, GPCR structure data and ligands with biased signalling, are analysed to investigate whether associated agents have reached clinical trials. We also outline the novel targets that are closest to reaching the market and assess the 'dark matter' of pharmaceutically unexplored GPCR targets and unexploited disease associations. Finally, we provide our data for extended analyses by the scientific community through a comprehensive public resource on GPCR drug data and statistics, and target mapping, which are integrated with the GPCR database (GPCRdb) 21 .
GPCR drugs and agents in clinical trials
Numbers of GPCR-targeted agents. All drugs approved in the United States are listed in the Drugs@FDA database. The primary resource for clinical trial registries is the US National Institutes of Health (ClinicalTrials.gov), which currently holds information on more than 256,000 clinical trials worldwide. The current status of agents in clinical trials is available in commercial databases such as CenterWatch's Drugs in Clinical Trials database, which covers more than 4,000 such agents that are in phase I to phase IV trials worldwide or that have been recently discontinued. However, none of these resources is comprehensive with respect to the targets of agents in trials, which can be collected from a combination of public resources, such as Drugbank 22 , Pharos 23 and Open Targets 24 (which also has a disease ontology), the literature [25] [26] [27] and company press releases. By manually curating CenterWatch's Drugs in Clinical Trials database (data extracted in July 2017) and crossreferencing with public sources, we were able to identify 475 approved drugs that target GPCRs. This accounts for approximately 34% of all FDA-approved drugs, which is similar to previously reported estimates (27-33%) on the number of GPCR-targeted drugs 1, 25, 27 . GPCR drug discovery has advanced rapidly. In the past 5 years, 69 new GPCR-targeting drugs have been approved by the US Food and Drug Administration (FDA) (see TABLE 1 for recent new molecular entities (NMEs)). The most recently approved GPCR-targeted drug is abaloparatide 28 , a parathyroid hormone (PTH1) receptor agonist that is used to treat postmenopausal women with osteoporosis. The number of agents currently in clinical trials is 321 (68% of the total number of approved drugs). Interestingly, 60 (19%) of the agents in trials target potentially novel GPCR targets for which a drug is not currently approved.
To study the distribution of established and currently investigated drug targets, we mapped approved drugs and clinical trial candidates onto the GPCR super family tree (FIGS 1,2) . The 475 approved drugs mediate their effects via 108 GPCR targets, accounting for 27% of the human non-olfactory GPCRs. Aminergic receptors, which are all established drug targets, are targeted by 314 of the approved drugs. Currently established GPCR drug targets are used by an average of 10.3 (median = 4) distinct approved agents. This indicates a near saturation of the current target space, and emphasizes the need to identify new druggable receptors in order to develop novel medications. The identification and exploitation of new targets is especially warranted for diseases with large unmet medical needs and few current viable targets, such as Alzheimer disease (AD).
Success rates of trials for GPCR-targeted agents. The FDA recently reported 70%, 33% and 25-30% success rates for phase I, II and III clinical trials, respectively, for all target families (see Further information). We estimated the success rates of GPCR-targeted agents in 2013-2017 (up to July 2017), by counting successes as agents that successfully reached at least one subsequent phase, and we counted failures as agents that were reported to be discontinued, terminated or withdrawn, or completed before this period but never progressed. This yielded GPCR-targeted agent success rates of 78%, 39% and 29% for phases I, II and III, respectively -slightly higher than the FDA's average for all investigated agents. This may reflect the high level of experience in targeting GPCRs. Both our and the FDA's analyses show a clear trend of more failures in later phases. A recent example is the small-molecule drug fasiglifam, an agonist of the free fatty acid 1 (FFA1) receptor (also known as GPR40). Fasiglifam showed efficacy in a phase III trial for diabetes 29 , but further development was terminated due to hepatotoxicity.
Popularity of peptide or protein receptors. We identified 66 potentially novel GPCR targets in clinical trials; that is, targets that are not yet modulated by approved drugs. Of these, 37 are peptide or protein-activated GPCRs (a selection of which are shown in TABLE 2), including the calcitonin gene-related peptide (CGRP) receptor for the treatment of migraine, the GPR55 receptor for the treatment of epilepsy and the apelin receptor for the treatment of cardiovascular disorders. Furthermore, the chemo kine receptors alone have 22 agents in clinical trials for the treatment of cancer, asthma, rheumatoid arthritis, chronic obstructive pulmonary disease (COPD) and HIV. The six members of the glucagon receptor family are also a focus of new approaches for the treatment of type 2 diabetes. Notably, although all recognize natural peptides or protein ligands, these targets span a breadth of receptor families and classes. This suggests that general new approaches, such as increased tractability with biologics, have contributed to the overall increased thera peutic targeting.
Orphan receptors enter clinical trials. Interestingly, current clinical trials feature several orphan GPCRs, for which endogenous ligands have not yet been discovered. These orphan GPCRs serve as potentially novel targets for the treatment of a diverse set of indications, such as GPR119 for the treatment of diabetes, leucine-rich repeatcontaining GPCR 4 (LGR4) and LGR5 for the treatment of gastrointestinal disease, GPR35 for the treatment of an allergic inflammatory condition, GPR55 as an antispasmodic target, the proto-oncogene Mas (MAS) for the treatment of thrombocytopenia and GPR84 for the treatment of ulcerative colitis. This indicates that the drug discovery process can still take place, and even advance, despite limited knowledge about the endogenous ligand or ligands and/or signalling pathways. The entry of an agent and target into clinical trials serves as an important qualifier, as it shows that animal studies, other preclinical data and disease relevance are promising enough to involve humans in subsequent investigations. It can be expected that public information on orphan receptors will increase as candidate drugs progress through clinical trials and/or upon approval. T r a c e a m in e G a l a n i n C h e m o k in e O r p h a n C l a s s A o r p h a n s
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Polypharmacology
Ligand binding to multiple targets, all of which contribute to the pharmacological response.
phase II trials for the treatment of rare genetic disorders of obesity, and is now in phase III development. Positive phase III data for a synthetic human angiotensin II peptide LJPC-501 in patients with catecholamine-resistant vasodilatory shock has recently been reported 33 , and an NDA is expected to be submitted by the end of 2017.
Overall, there are early indications that modalities other than small molecules are becoming more popular for agents targeting GPCRs, as the share of peptides, mAbs and other recombinant proteins 31 being studied in phase I trials is higher than that in later phases (FIG. 3a) .
More allosteric modulators in early stage clinical trials.
Allosteric modulators offer an attractive novel mechanism: remotely modulating the activity that is induced at the binding site of the physiological ligand. This often has advantages, such as higher selectivity at the target (perhaps by binding to a less well-conserved site across a receptor family with the same endogenous ligand), temporal selectivity (action linked to the release of the endogenous ligand) and sometimes also functional selectivity through biased signalling 19 , as shown for the FFA1 receptor 34, 35 . Approved allosteric modulators include cinacalcet, a positive allosteric modulator of the calcium-sensing (CaS) receptor for the treatment of hyperparathyroidism, and maraviroc, a negative allosteric modulator of the chemokine receptor CCR5 for the prevention of cellular entry of HIV-1. Allosteric modulation has also been suggested as a viable option for the peptide hormone class B receptors, which have not been tractable when targeting the orthosteric site 18 . The allosteric database currently lists 27,769 GPCR-targeted allosteric modulators 36 , and several positive and negative allosteric modulators are in phase I and phase II trials, respectively (FIG. 3b) . There is also an indication that agonists may be more prevalent and that antagonists may be less prevalent in phase I trials. Interestingly, several of the allosteric modulators currently in clinical trials are combination therapies with orthosteric ligands for the treatment of CNS disorders 37 .
Increasing focus on target selectivity rather than polypharmacology. Many drugs are known to exert their therapeutic effect through multiple targets; that is, polypharmacology. To complement the previous studies by Santos et al. 27 and Overington et al. 25 , which assigned 1:1 relationships between approved drugs and their targets, our annotation covers all primary and secondary targets, including those for agents in clinical trials. Interestingly, a trend was found for increasing selectivity (decreasing polypharmacology) for earlier trials (FIG. 3c) . Furthermore, the currently investigated phase I agents have fewer targets than the discontinued agents, further suggesting an increasing focus on target selectivity rather than on polypharmacology.
Polypharmacology could still lead to future opportunities with established targets, as specifically discussed for the dopaminergic system 38, 39 . Drugs that exhibit polypharmacology at dopamine and serotonin receptors include, for example, haloperidol, amoxapine and asenapine 39 . Amitriptyline, as an example of a tricyclic antidepressant, also has high affinity at muscarinic and histamine H 1 receptors (which can be useful therapeutically). Furthermore, antimuscarinics used in bladder dysfunction are non-selective across the range of five human receptors, although the primary targets seem to be the muscarinic acetylcholine M 2 and M 3 receptors.
Trends in disease indications
Our data show that the indications for GPCR-targeted agents are expanding from historically popular areas, such as hypertension, allergy, analgesics, schizophrenia and depression, into novel areas such as AD and obesity (FIG. 4a) . Furthermore, in the past 5 years, GPCRs have also been targeted for new indications, including multiple sclerosis (MS), smoking cessation, short bowel syndrome and hypocalcaemia. Major trends in the indications of GPCR-targeted agents are highlighted below. Central nervous system disorders remain highly represented among the indications of GPCR-targeted agents.
Grouping the indications of approved GPCR-targeted drugs into higher-level disease terms using the Open Target 24 ontology shows that central nervous system (CNS) diseases are the most abundant, accounting for 124 (26%) of all approved GPCR-targeted drugs. Furthermore, at least 79 GPCR-targeted agents are currently in clinical trials for CNS indications, demonstrating a continued strong interest. An analysis of receptor baseline expression from the human protein atlas 40 , and studies on the mouse brain 41 , show that more than 50% of all non-olfactory GPCRs are expressed in the cerebral cortex. Malfunctions in GPCR-mediated neurotransmission can lead to multiple neurological and psychiatric disorders, making GPCRs promising targets 42 . MS, AD, Huntington disease (HD) and fragile X syndrome (FXS) are highlighted below.
MS, the most common chronic autoimmune disorder that affects the CNS, is caused by damage to the insulating myelin covers of axons. Data from clinical studies and animal models have uncovered several GPCRs involved in the pathogenesis of MS 12 , and one GPCR-targeted drug has been approved: fingolimod, a sphingosine 1-phosphate receptor 1 (S1P 1 ) modulator, which reduces relapse rates and the risk of disability progression 43 . Several other S1P 1 receptor modulators -ozanimod, ponesimod and siponimod -are currently in phase II and phase III trials. These drugs are expected to have advantages over fingolimod, such as higher selectivity for the S1P 1 receptor, faster clearance and improved tissue penetration 44 . Other MS targets include the cannabinoid receptors. A tetrahydrocannabinol and cannabidiol (THC-CBD) oromucosal spray has been tested in phase II and phase III studies and has been shown to reduce spasticity 45 . A GPR55-selective compound currently in phase II trials may also potentially be better tolerated than comparable antispasmodics. Taken together, the multitude of agents and targets in late-stage clinical trials indicates that additional MS therapies acting through GPCRs are likely to emerge in the near future.
GPCRs are also involved in several neurotransmitter systems that are associated with AD; glutamatergic, serotonergic, adrenergic and peptidergic pathways in particular are deregulated in this neurodegenerative disorder 46 . Targeting these systems might protect against disease progression by modulating the formation of amyloid-β plaques (one of the cardinal disease features) or aberrant signalling following plaque formation 46 . There is a huge unmet medical need for new therapies for AD, particularly those that might modify disease progression, as the small number of existing therapies (most of which act by increasing levels of acetylcholine by inhibiting its breakdown by acetylcholinesterase) only have limited effectiveness at improving disease symptoms. Leuprolide, a gonadotropin-releasing hormone receptor agonist approved for treating prostate cancer, has been tested in a phase III trial for AD, but it failed to meet the primary or secondary end points, although there were signs of an effect on disease progression in patients taking an acetylcholinesterase inhibitor 47 . An additional nine GPCR-targeted agents are currently in clinical trials for the treatment of AD (FIG. 4) . Serotonin (5-HT) receptor modulators are of particular interest, including 5-HT 6 receptor antagonists to improve disease symptoms (rather than to modify the disease course) by promoting the release of acetylcholine 48 . However, Lundbeck recently terminated the development of their 5-HT 6 receptor antagonist idalopirdine owing to insufficient efficacy in phase III trials. Pfizer also terminated a 5-HT 6 receptor antagonist PF-05212377 due to lack of efficacy after a phase II trial in 2016. A phase III trial of another 5-HT 6 receptor antagonist, intepirdine, licensed by Axovant Sciences from GlaxoSmithKline, failed very recently, but intepirdine is still being investigated in patients with dementia with Lewy bodies.
GPCRs are also potential targets for HD, another neuro degenerative disorder 49 , for which current therapies can also only improve some symptoms. HD is caused by numerous repetitions of CAG-triplet repeats within the Huntingtin gene (HTT), leading to the expression of an abnormal pathogenic huntingtin protein and subsequent cell damage; however, the underlying mechanisms are not fully elucidated. Several GPCR pathways are downregulated in patients with HD, and two GPCR-targeted agents are currently in clinical trials for HD: the adenosine A 1 receptor antagonist pbf-999 (which is in phase I trials) and the dopamine D 2 receptor antagonist pridopidine (which is in phase III trials).
Finally, GPCRs have attracted considerable investment as targets for FXS -the most common inherited form of intellectual disability and autism -which is caused by alterations in FMR1, the gene coding for FMRP. Studies in Fmr1-knockout mice, which have been widely used as an animal model for FXS, showed that the inhibition of the metabotropic glutamate receptor 5 (mGlu 5 ) improved synaptic function in these animals and highlighted the importance of mGlu 5 in FXS 37 . However, negative allosteric modulators of mGlu 5 , such as basimglurant, mavoglurant and STX107, failed in phase II trials, as no improvement over placebo could be demonstrated. Agents targeting the GABA B receptor, which improved function in Fmr1-knockout mice, have also been clinically investigated for FXS. However, despite some indications of efficacy in a phase II trial with the GABA B agonist arbaclofen 50 , subsequent phase III trials failed due to lack of efficacy compared with placebo. In 
Modes of action
Receptor activity defined as ligand stimulation (agonism), blocking (antagonism), inhibition (inverse agonism), or negative or positive allosteric modulation.
Diabetes is highly represented among the indications for GPCR-targeted agents currently in clinical trials.
The growing market share of metabolic disease medications 51 is reflected in the high number of GPCR-targeted agents in clinical trials for diabetes and obesity, with 27 agents targeting GPCRs for diabetes and seven for obesity (together constituting ~9% of the total number of agents in clinical trials). There are an estimated 415 million people worldwide with diabetes mellitus 52 , 90% of whom have type 2 diabetes. In contrast to type 1 diabetes, which requires regular insulin injections due to the failure of the pancreas to produce enough insulin, type 2 diabetes can be treated with medications that stimulate insulin secretion or that increase insulin sensitivity 53 . The first GPCR-targeted drug for type 2 diabetes -the GLP1 receptor agonist (or incretin mimetic) exenatide -was approved in 2005. As noted above, there are now several other approved peptidic GLP1 receptor agonists, including liraglutide, lixisenatide, dulaglutide and albiglutide. They differ in their durations of action, but all are formulated as injectable drugs. However, semaglutide, a onceweekly GLP1 analogue that improved glycaemic control in a phase II trial 54 is now also being tested for oral dosing in phase III trials. Advances in small-molecule screening, including structure-based techniques 9 , have identified new non-peptide agonists of the GLP1 receptor, including the orally bioavailable TTP273, which is currently in phase II trials. The challenges of treating type 2 diabetes and associated diseases such as diabetic neuropathy and foot ulcers have catalysed investment in further GPCR-targeted agents 32, 55 . Currently, 11 GPCRs mediate the therapeutic effects of approved treatments for these conditions, and agents targeting a further 25 GPCRs are under investigation in clinical trials. Among them is MBX-2982, which is a small-molecule GPR119 agonist currently in phase II trials. MBX-2982 increases both insulin secretion and GLP1 release 56, 57 . Another novel target for which agonists stimulate insulin secretion is the FFA1 receptor 34 . Despite the recently discontinued development of the small-molecule agonist fasiglifam (TAK-875) due to hepatotoxicity (mentioned above) 29 , the FFA1 receptor remains a viable target, albeit with a need for further characterization of its signalling spectrum, and at least one FFA1 receptor modulator, LY2881835, is in clinical trials. Another novel target for the treatment of diabetes is the dopamine D 2 receptor. The first dopaminergic agent, bromocriptine, was recently approved for improved glycaemic control and glucose tolerance in type 2 diabetes 58 . Opportunities are emerging for GPCR-targeted agents in oncology. Currently, 21 approved drugs with an antineoplastic indication mediate their effects via 14 distinct GPCRs. Among these are degarelix, a gonadotropinreleasing hormone (GnRH) receptor antagonist that is approved for patients with advanced prostate cancer, and vismodegib, a smoothened (SMO) receptor inhibitor for the treatment of basal cell carcinoma. The most recent FDA approval for a GPCR-targeted agent in oncology was in 2015 for another SMO receptor inhibitor, sonidegib, which was also approved for the treatment of basal cell carcinoma. An additional 23 GPCR-targeted agents for treating cancer -seven of which have potentially novel targets -are currently in clinical trials. Chemokine receptors and proteins in the WNT pathway are among the novel GPCR targets being pursued 13 , often with peptide or mAb therapeutics. For example, CCR2 is the target of the mAb plozalizumab, which is in phase I trials for melanoma, and the small-molecule CCR2 inhibitor CCX872 is in phase I trials for advanced pancreatic cancer. Vantictumab (also known as OMP-18R5) -a mAb specific for the Frizzled-7 receptor (FZD 7 ) that has been tested in clinical trials for breast and pancreatic cancer -targets the WNT signalling pathway, which is dysregulated in many cancers, leading to cancer stem cell activity and tumour growth Furthermore, several other GPCRs have been suggested as potential cancer targets based on mRNA expression analyses of tumours 60 . In addition to directly targeting GPCR-mediated cancer pathways, overexpressed receptor homodimers and heterodimers that are overexpressed in certain cancers might function as selective markers for cancer treatment 61 . Drugs for established GPCR targets in oncology also continue to be investigated, including GnRH antagonists such as relugolix for prostate cancer. GnRH antagonists such as relugolix and elagolix are also being investigated for other hormone-related indications such as endometriosis.
Repurposing of existing GPCR-targeted drugs for new indications.
The repurposing of existing drugs for new indications can reduce the time and cost of bringing a therapeutic to market 62 . Of the approved GPCRtargeted drugs, 156 (33%) have more than one indication and the overall average is 1.5 indications (FIG. 4b) , demonstrating that many such drugs are already used for several indications. Agents in clinical trials have a similar average number of indications to that of currently approved drugs.
Ongoing clinical trials are evaluating the potential of repurposing 23 (5%) of the approved GPCR-targeted drugs, which account for ~8%, ~7% and ~14% of the agent-indication pairs in phase I, II and III trials, respectively (FIG. 4c) . Repurposed agents occur as frequently in ongoing and discontinued trials, indicating that they do not necessarily succeed more often than new agents. This suggests that efficacy is typically the limiting factor, rather than safety.
Emerging trends and opportunities GPCR knowledge in the literature is disproportionately focused. More than 50% of the human genome-encoded non-olfactory GPCRs (n = 224) remain therapeutically unexploited (FIG. 2) . Drug targets are often first identified and explored in an academic environment. However, due to the long time span of drug development, there is usually a lag time of many years or even decades before such discoveries are translated into marketed drugs. For this reason, we investigated how research results in the form of publication output relate to drug discovery efforts, and whether this output could indicate new trends in GPCR-targeted drug discovery.
GPCR research is an area of immense exploration.
Gene and protein name searches in PubMed abstracts show that the chemokine receptor type 4 (CXCR4) and the putative adhesion G protein-coupled receptor E4P (ADGRE4P; also known as AGRE4) are mentioned in the abstracts of the most publications (11, 123) and fewest publications (0; although this may be partly due to new nomenclature for adhesion receptors), respectively (FIG. 5a; note logarithmic scale). GPCRs with approved drugs or agents in clinical trials are mentioned in the abstracts of an average of ~400 publications, whereas this figure is only 20 for non-targeted receptors. Receptors with a crystal structure (FIG. 5b) are mentioned in the abstracts of many publications (this probably actually reflects the fact that crystallization efforts in the past decade or so initially focused on therapeutically important and well-characterized GPCRs). Orphan receptors (FIG. 5a; shown in light red) with unknown physiological agonists and functions often have very few mentions in publication abstracts. Nonetheless, some orphan receptors, such as GPR143 and GPR15, are mentioned in more than 100 article abstracts. The disproportionate data foundation underlines the fact that the research efforts on many GPCRs are still in their infancy, and that further characterization is needed to assess their role in physiology and pathophysiology. This is in accordance with a general knowledge deficit and lack of funding for many understudied human proteins, as has been recently highlighted by a US National Institutes of Health (NIH) programme called Illuminating the Druggable Genome 2 .
Emerging targets based on disease associations, tool compounds and patents. Approximately 63% of human GPCRs have at least one ligand reported in ChEMBL (FIG. 5c) , including various promising emerging targets for which agents have not yet been explored in clinical trials. For example, the neuropeptide S system, which was first described only a few years ago, has been associated with several mental illnesses 63 , and the relaxin family receptors have recently been examined as potential targets for the treatment of addiction, anxiety, obesity and anorexia 64 . With a range of specific antagonists at hand, the modulation of formyl peptide receptors has been suggested to inhibit tumour angiogenesis in glioblastoma and other cancers 65 . Bombesin 3 receptor-knockout mice develop metabolic disturbances, obesity and hypertension 66, 67 . The disruption of galanin receptor signalling in several preclinical studies has indicated that this system is involved in a range of pathologies, including AD, epilepsy, depression and cancer 68, 69 . The aforementioned target families are expected to be among the first to enter clinical trials in the coming years due to their promising preclinical findings.
To further evaluate potentially active pharmaceutical investigations into promising new targets, we analysed patents filed between 2014 and October 2016 in medical sciences through the World Intellectual Property Organization (WIPO) (FIG. 5d) . On the basis of these filings, chemokine receptors, with more than 100 filed patents, are currently the most vigorously pursued target family, followed by CaS receptors (n = 11), glycoprotein hormone receptors (n = 9) and Frizzled receptors (n = 9). In addition, 35 patents on orphan receptors, including GPR84, GPR1, GPR17 and LGR5, have also been filed in this timeframe. Finally, targets for which there are approved drugs or drugs in clinical trials tend to have a high number of associated publications and compounds in ChEMBL (FIG. 5e) .
Untapped GPCRs as a source for new drug targets in a variety of disease areas. The diverse roles of GPCRs are reflected by our analysis of target disease associations from Open Targets (FIG. 6) , which shows that GPCRs are associated with nearly every aspect of human pathophysiology. Strikingly, untapped or emerging targets -that is, GPCRs that have not yet been targeted or those for which agents are in trials but none have yet been approved -are found in 17 and 19 of the 20 displayed categories, respectively. Most emerging targets for which agents are in trials have already reached phase III, indicating that they may soon transition to established targets. The largest share of GPCRs with a disease association that has not yet been investigated at all clinically are found for genetic disorders, followed by eye diseases and the immune system.The exploitation of the emerging targets will be facilitated by new avenues in GPCR drug discovery, such as the application of structural data, biased signalling, allosteric modulation and de-orphanization (described below).
Impact of GPCR structures on drug discovery. Structurebased drug design has long had a valuable role in drug discovery, particularly for drugs with enzyme targets, such as the HIV protease inhibitor indinavir 70 , the tyrosine kinase inhibitor imatinib 71 and the influenza neura minidase inhibitor zanamivir 72 . However, until recently, major challenges in applying X-ray crystallography to Nature Reviews | Drug Discovery GPCRs limited the potential for structure-based drug design for such targets. However, thanks to recent breakthroughs in GPCR crystallography 73, 74 , 44 distinct GPCR structures and 205 ligand-receptor complexes are now available across all human GPCR classes A-C and F 21 (FIG. 7) . This has paved the way for novel lead discovery through virtual screening and better off-target rationalization 75, 76 . For example, recent docking experiments against the μ-opioid receptor structure identified PZM21, a G i protein-biased agonist with potency and efficacy similar to morphine, but with reduced adverse effects in mice 77 . In another exciting example, two chemokine receptor structures -for CCR9 and CCR2 -revealed a previously unknown intracellular binding pocket, which might provide a new strategy for drug design 78 . We investigated whether the availability of crystal structures has had a measurable impact on the number of agents in clinical trials. FIGURE 7a shows that most of the receptors with many approved drugs (red bars) have an early crystal structure published in 2007-2012, with the exception of the muscarinic M 1 receptor (ACM1) from 2016. It is likely that these receptors were selected for crystallization based on their high therapeutic relevance, such as many and early validated disease associations. However, these targets also have a significant proportion of agents in phase I and phase II trials, in which the structural templates could have been available long enough to contribute to the lead discovery and/or optimization processes.
The real impact of structural data may be underestimated due to unpublished proprietary structures. For example, Receptos announced in January 2011 that they were targeting the S1P 1 receptor with a proprietary structure, which was not published until the following year. This S1P 1 agonist, ozanimod (which is now being developed by Celgene following their acquisition of Receptos), is expected to be submitted for FDA approval in 2017. Furthermore, Heptares Therapeutics' pipeline (see Further information) currently lists ten specified, and an even larger number of undisclosed, targets for which agents are in preclinical and clinical trials. Known structure-based candidates that target GPCRs include agents that target the μ-opioid receptor for pain 77 , M 1 and M 4 muscarinic receptors for AD, the mGlu 5 receptor for psychiatric disorders, orexin receptor 2 (OX 2 ; also known as HCRTR2) for narcolepsy, proteinase-activated receptor 2 (PAR2) for inflammatory disorders (see Heptares pipeline in Further information) and the adenosine A 2A receptor for cancer 79 .
Biased signalling as a novel mechanism for functional selectivity. Activating the appropriate cellular response through one of the four major G protein families and their intracellular effectors (such as adenylyl cyclase and phospholipase C) or through β-arrestin-dependent activation of kinases and others, is crucial for a favourable physiological response [80] [81] [82] . Recent discoveries of molecules that preferentially trigger one of these pathwaysreferred to as biased agonists -offer a new mechanism for reducing side effects 8, 20, 83, 84 . This has led to the idea of distinct receptor conformational states that are stabilized by different ligands, and can lead to activation of specific signalling and regulatory proteins 85 . Several promising agents with bias through β-arrestin, a G protein or allosteric modulation are being investigated in preclinical studies, as well as clinical trials 8 . Most notable is the μ-opioid receptor ligand oliceridine (TRV130), currently in phase III trials, which was granted 'Breakthrough Therapy' designation by the FDA owing to its improved analgesic profile 86 . Oliceridine, and its current phase I follow-on agent TRV734, do not engage the β-arrestin pathway, which is associated with opioid-induced respiratory depression and constipation 87 . Conversely, no G protein engagement was observed for the β-arrestin-biased ligand TRV027, which targets the angiotensin II type 1 receptor and which is a drug candidate for the treatment of acute heart failure 88 . However, in May 2016, Trevena announced that TRV027 had failed to meet the primary or secondary end points in a phase IIb trial.
Therapeutic implications for biased agonists have only begun to be elucidated for a number of GPCR systems, including adrenergic, angiotensin, opioid, dopamine, serotonin and chemokine receptors 7 . More knowledge It is important to note that the association of a GPCR target with an approved drug with a disease type, system or organ does not mean that a drug has been approved for that disease type, system or organ (for example, many genetic disorders for which an association exists may not actually have an approved GPCR drug). Disease associations have been agglomerated from the Open Targets platform by combining association scores above a value of 0.5 (at least one-half of the highest association confidence). The association score summarizes the strength of evidence from each data source (genome-wide association studies, genetic variants, expression data and animal models) (see Further information). Three ontology terms, 'measurement', 'phenotype' and 'biological process', were excluded as they cannot be interpreted as a distinct category. It should be noted that receptors can be associated with multiple systems. of the signalling repertoire of GPCRs will be required to fully exploit the potential of biased signalling and to fine-tune intracellular responses to therapy 89 . New ways to validate biased signalling in animal models will help the development of the tools needed to transition biased ligands towards preclinical development as drug candidates and beyond 90 .
Outlook for targeting GPCRs GPCR drug discovery has gained new momentum, as demonstrated by the large number of new drug targets and the scientific impetus in GPCR structural biology, pharmacology and modelling. Although it is to be expected that many of the GPCR-targeted agents currently in clinical trials will not ultimately gain regulatory approval, the demonstrated druggability of the GPCR protein family and the important role of GPCRs in diseases such as diabetes, obesity, AD and psychiatric disorders, provide a strong driving force for continued drug discovery and development efforts in this field.
As the physiology and pathophysiology of GPCRs becomes better characterized, certain groups of receptors may prove intractable, whereas others may expand the druggable 'GPCRome' . There is emerging evidence of excreted gut microbiota metabolites that serve as ligands for GPCRs and thereby influence hormone release 91, 92 .
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